Genentech to expand California biologics manufacturing facilities

Published: 14-Oct-2013
Manufacturing Finance Pharmaceutical

Investment of $285m will create more than 250 new jobs


Genentech, a member of the Roche Group, is to invest more than US$285m in an expansion of its biologics manufacturing facilities in Vacaville and Oceanside, California.

The company’s US manufacturing network spans three locations in California – South San Francisco, Vacaville, and Oceanside – and Hillsboro, Oregon. When the expansion is complete, Genentech’s Vacaville facility will not only be the largest producer of biologic medicines for the Roche Group but also the largest biotech manufacturing facility in the world.

'This investment and expansion will result in the addition of more than 250 new jobs at the Vacaville and Oceanside facilities over the next four years, bringing the total number of Genentech manufacturing jobs in California to close to 3,000,' said Ian Clark, Chief Executive Officer of Genentech. 'California has always had an impressive skilled workforce that has allowed Genentech to hire diverse and talented individuals in various disciplines,' he added.

  • Companies:
  • Genentech
  • Roche Group
See more

You may also like

Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Read more
Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Roche's breast cancer combination therapy Itovebi bags FDA approval

Itovebi plus palbociclib and fulvestrant reduced the risk of disease progression or death significantly in patients
Finance

Lonza completes acquisition of large-scale biologics site in Vacaville (US) from Roche

Acquisition extends Lonza’s US Biologics footprint with a significant presence on the West Coast, complementing its existing global manufacturing network
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Regulatory

Roche receives approval for PiaSky to treat patients with PNH in Europe

The subcutaneous C5 inhibitor stops the patients from having to attend the clinic to receive IV infusions for PNH management
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Finance

Swiss medtech investment surpasses last year, biotech run rates are up

Fuelled by innovation, Swiss medtech investment already surpasses last year, while biotech run rates are up
Subscribe now